# Treatment of Cognitive Impairment in Men With Schizophrenia (MK5757-005)(COMPLETED)

> **NCT00848484** · PHASE2 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 54 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** MK5757
- **DRUG:** Comparator: Placebo

## Key facts

- **NCT ID:** NCT00848484
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10
- **Primary completion:** 2009-06
- **Final completion:** 2009-06
- **Target enrollment:** 54 (ACTUAL)
- **Last updated:** 2015-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00848484

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00848484, "Treatment of Cognitive Impairment in Men With Schizophrenia (MK5757-005)(COMPLETED)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00848484. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*